📊 ESMC Key Takeaways
Is ESMC a Good Investment? Thesis Analysis
Escalon Medical is a distressed company with deteriorating fundamentals, burning cash at an unsustainable rate while generating minimal revenue growth. Negative operating cash flow of -432.4K, combined with persistent operating losses and a weak equity base of only 1.8M, indicates the company is in financial distress with limited runway.
Why Buy ESMC? Key Strengths
- Low leverage with debt-to-equity of only 0.01x provides some financial flexibility
- Current ratio of 1.65x indicates adequate short-term liquidity to cover immediate obligations
- Established presence in electromedical apparatus sector with existing revenue base of 6.3M
ESMC Investment Risks to Consider
- Negative free cash flow of -436.8K annually indicates unsustainable cash burn with only 337.4K cash available
- Operating losses of -104.0K and net losses of -142.2K show inability to generate profitability at current scale
- Minimal revenue growth of 0.5% YoY combined with negative operating margins suggests business model deterioration or lack of market demand
- Cash runway appears critically limited; at current burn rate, available cash depleted within months
- No insider buying activity in last 90 days, suggesting lack of management confidence
Key Metrics to Watch
- Operating cash flow - must return to positive territory
- Revenue growth rate - currently stagnant; needs 10%+ growth to stabilize
- Cash balance and runway - monitor for financing needs or dilution events
- Path to operating profitability - critical for survival
ESMC Financial Metrics
💡 AI Analyst Insight
ESCALON MEDICAL CORP presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ESMC Profitability Ratios
ESMC vs Healthcare Sector
How ESCALON MEDICAL CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ESMC Overvalued or Undervalued?
Based on fundamental analysis, ESCALON MEDICAL CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ESMC Balance Sheet & Liquidity
ESMC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ESCALON MEDICAL CORP's revenue has grown significantly by 15% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
ESMC Growth Metrics (YoY)
ESMC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$21.2K | $-0.02 |
| Q2 2025 | $2.9M | -$21.2K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ESMC Capital Allocation
ESMC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ESCALON MEDICAL CORP (CIK: 0000862668)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ESMC
What is the AI rating for ESMC?
ESCALON MEDICAL CORP (ESMC) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ESMC's key strengths?
Claude: Low leverage with debt-to-equity of only 0.01x provides some financial flexibility. Current ratio of 1.65x indicates adequate short-term liquidity to cover immediate obligations.
What are the risks of investing in ESMC?
Claude: Negative free cash flow of -436.8K annually indicates unsustainable cash burn with only 337.4K cash available. Operating losses of -104.0K and net losses of -142.2K show inability to generate profitability at current scale.
What is ESMC's revenue and growth?
ESCALON MEDICAL CORP reported revenue of $6.3M.
Does ESMC pay dividends?
ESCALON MEDICAL CORP does not currently pay dividends.
Where can I find ESMC SEC filings?
Official SEC filings for ESCALON MEDICAL CORP (CIK: 0000862668) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ESMC's EPS?
ESCALON MEDICAL CORP has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ESMC a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, ESCALON MEDICAL CORP has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ESMC stock overvalued or undervalued?
Valuation metrics for ESMC: ROE of -8.0% (sector avg: 15%), net margin of -2.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ESMC stock in 2026?
Our dual AI analysis gives ESCALON MEDICAL CORP a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ESMC's free cash flow?
ESCALON MEDICAL CORP's operating cash flow is $-432.4K, with capital expenditures of $4.4K. FCF margin is -7.0%.
How does ESMC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2.3% (avg: 12%), ROE -8.0% (avg: 15%), current ratio 1.65 (avg: 2).